Índice
Literatura académica sobre el tema "Inhibiteurs CDK4"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Inhibiteurs CDK4".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Inhibiteurs CDK4"
Massard, V., A. Harlé, L. Uwer y J. L. Merlin. "Mutations du gène ESR1 : du fondamental à la clinique". Oncologie 21, n.º 1-4 (enero de 2019): 29–32. http://dx.doi.org/10.3166/onco-2019-0027.
Texto completoGonçalves, Anthony. "Inhibiteurs de CDK4/6 : biomarqueurs, mécanismes de résistance et étude de l’ADN tumoral circulant potentielle". Bulletin du Cancer 105, n.º 6 (junio de 2018): 545–46. http://dx.doi.org/10.1016/j.bulcan.2018.04.003.
Texto completoBaldé, S. "C95: Place de l’Evérolimus dans le cancer du sein avancé M+ RH+/Her2- : Stratégies thérapeutiques". African Journal of Oncology 2, n.º 1 Supplement (1 de marzo de 2022): S40—S41. http://dx.doi.org/10.54266/ajo.2.1s.c95.hcih5777.
Texto completoVallet, Sonia, Noopur Raje, Kenji Ishitsuka, Teru Hideshima, Klaus Podar, Petter Veiby, Iris Breitkreutz et al. "MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation." Blood 108, n.º 11 (16 de noviembre de 2006): 1636. http://dx.doi.org/10.1182/blood.v108.11.1636.1636.
Texto completo"Inhibiteurs de CDK4/6 et cancers du sein, du métastatique à l’adjuvant : données cliniques". Innovations & Thérapeutiques en Oncologie 8, n.º 3 (1 de mayo de 2022): 157–65. http://dx.doi.org/10.1684/ito.2022.0317.
Texto completoTesis sobre el tema "Inhibiteurs CDK4"
Richard, Mathilde. "Les vésicules extracellulaires plasmatiques, de potentiels biomarqueurs de suivi thérapeutique dans le cancer du sein métastatique". Electronic Thesis or Diss., Nantes Université, 2024. http://www.theses.fr/2024NANU1012.
Texto completoExtracellular vesicles (EVs), nanoparticle entities derived from cellular membranes, transport biological materials and circulate through body fluids. They are currently positioned as potential biomarkers for cancer progression and therapeutic response. Despite numerous innovative therapeutic strategies improving management and survival rates, breast cancer (BC) remains the leading cause of cancer-related death in women. Thus, the identification of specific biomarkers represents a significant hope for monitoring disease progression and predicting treatment efficacy. The primary objective of this research project was to characterize plasma EVs as potential biomarkers of response to CDK4/6 inhibitors treatment in metastatic breast cancer (MBC) patients with hormone receptor-positive (HR+) status. To facilitate translational research on the use of EVs as circulating biomarkers, we established a three-step procedure clinically applicable: 1- EVs were isolated from plasma using semi-automated size-exclusion chromatography (SEC); 2- plasma EV concentration (i.e., vesiclemia) was determined using the VideoDrop, a microscope utilizing interferometry; and 3- the sphingo-lipidic signature was analyzed by mass spectrometry. We initially measured vesiclemia in a healthy population to establish a reference value, accounting for sex and age. Subsequently, we monitored the physiological vesiclemia evolution over 24 months and compared it with that of MBC HR+ patients at different treatment stages. Our results reveal that an increase in vesiclemia two months after treatment initiation is significantly associated with early disease progression. Furthermore, we analyzed the lipid composition of EVs to reinforce their potential as biomarkers of disease progression. A specific signature of 16 EV-associated sphingolipids enabled us to establish a score identifying CDK4/6 inhibitor-resistant patients with82% accuracy. Finally, this characterization of plasma EVs as biomarkers led us to explore their potential in MBC patients with triple-negative and HER2+ status
Prevel, Camille. "Développement de biosenseurs fluorescents et d’inhibiteurs pour suivre et cibler CDK4/cycline D dans le mélanome". Thesis, Montpellier, 2015. http://www.theses.fr/2015MONT3505/document.
Texto completoCDK/cyclins play a central role in coordinating cell cycle progression, and in sustaining proliferation of cancer cells, thereby constituting established cancer biomarkers and attractive pharmacological targets. In particular, CDK4/cyclin D, which is responsible for coordinating cell cycle progression through G1 into S phase, is a relevant target in several cancers including melanoma, associated with mutation of CDK4, cyclin D, p16INK4a and pRb.As there are no sensitive and direct approaches to probe CDK4/cyclin D activity in physiological and pathological conditions, the first goal of my thesis has consisted in engineering a fluorescent biosensor to probe this kinase in vitro and in cellulo. Once characterized and validated in vitro, the biosensor was applied to detect CDK4/cyclin D alterations in biopsies from human skin and melanoma xenografts in fluorescence-based activity assays, and in living cancer cells by fluorescence microscopy and timelapse imaging.Moreover, only few inhibitors are currently available to target CDK4/cyclin D and most of them bind the ATP pocket. As such, the second major goal of my thesis project has consisted in identifying non-ATP competitive inhibitors, either through rational design of peptides or by screening small molecule libraries. To this aim, two fluorescent biosensors were engineered which discriminate compounds that target the interface between CDK4 and cyclin D, or that perturb the conformational dynamics of CDK4, respectively, from ATP-pocket binding compounds. Fluorescence-based screening assays performed with these biosensors lead to identification of hits, which were validated and characterized in vitro and in cell proliferation assays, and which constitute promising candidates for selective chemotherapy in melanoma
Delmas, Christelle. "Modes de régulation de l'inhibiteur de CDKs, p27kip1, par les MAPKsp42/p44". Toulouse 3, 2003. http://www.theses.fr/2003TOU30006.
Texto completoBacevic, Katarina. "Cdk2 as a model for studying evolutionary selection and therapeutic responses in proliferating cancer cells". Thesis, Montpellier, 2016. http://www.theses.fr/2016MONTT184.
Texto completoCyclin-dependent kinases (Cdk) are essential regulators of the cell cycle that support cell proliferation and are often deregulated in cancer. While Cdk1 is an essential regulator of the cell cycle, Cdk2 is not required for cell cycle progression but promotes tumorigenesis. Therefore, Cdk2 is a promising drug target. Many Cdk inhibitors have been developed and are currently undergoing clinical trials. Darwinian selection can be modelled mathematically, and such studies have shown that even marginal selective advantages can be of great importance in outcomes of cell-cell competition and cancer progression. We hypothesised that the non-essential role of Cdk2 for cell cycle progression may mean that it is a good target for cancer therapy as continual inhibition should be tolerated and should counteract deregulated cell proliferation in cancer. However, as with all chemotherapeutic agents, the development of clinical resistance is likely. We further hypothesized that applying a low-dose treatment with Cdk2 inhibitors should minimize chances of developing resistance, by maintaining competition between robustly proliferating cells that are sensitive to treatment, and resistant cells.The aim of the thesis was to investigate whether Cdk2 confers a proliferative advantage to cancer cells, whether cells can develop resistance to Cdk inhibitors, and if so, whether the mechanisms allowing resistance reduce cellular proliferative fitness.To answer these questions, we have created cell lines with varying degrees of resistance to a selective Cdk2 inhibitor (that at high doses, also inhibits Cdk1) and have characterised their proliferation capacity in comparison with parental cells and isogenic Cdk2 knockout cells. Although in these cells the Cdk2 gene is not mutated and the expression of Cdk2 protein remained unaltered, the kinase activity of Cdk2 is decreased. Similarly, Cdk2 gene knockout (Cdk2 KO) cells have reduced sensitivity to Cdk2 inhibition. Inhibitor-resistant cells proliferate efficiently but are outcompeted by parental, inhibitor-sensitive cells in competition experiments, confirming that inhibitor resistance entails a selective disadvantage. We found that the proliferation of both Cdk2 knockout and inhibitor-resistant (R50) cells is sensitive to nutrient and glucose depletion as well as hypoxia, despite a normal oxygen consumption rate, indicating increased aerobic glycolysis. R50 cells have highly upregulated Cdk6, which may contribute to resistance to Cdk2 inhibition. Moreover, they are sensitised to Cdk4/6 inhibition, which is currently authorised as a treatment for some classes of breast cancer. Finally, Cdk2 knockout cells have an impaired S-phase checkpoint. These results suggest that pharmacological inhibitors targeting Cdk2 might be synthetically lethal with other treatments, eg inhibition of DNA replication, of glycolysis, or of Cdk6. This might diminish cancer cell proliferation and prevent emergence of therapeutic resistance
Bettayeb, Karima. "Optimisation et caractérisation de nouveaux inhibiteurs pharmacologiques de kinases cycline-dépendantes (CDKs)". Rennes 1, 2008. http://www.theses.fr/2008REN1S025.
Texto completoCyclin-dependent kinases (CDKs) are key regulators of cell division cycle (CDK1, 2, 3, 4, 6, 7), apoptosis (CDK1, 5), and transcription (CDK7, 9). Pharmacological inhibitors of CDKs constitute a new family of potential antitumor agents: ten are under clinical trials, among which roscovitine, was discovered in our laboratory. My thesis is about identification, optimisation and characterization of biochemical and cellular effects of three new kinase inhibitory classes: 7-bromo-indirubins (7BIO), meriolin and new analogs of roscovitine (N&N1 and C&R8). 7BIO induces non-apoptotic cell death through an unknown mechanism (no release of cytochrome C, nor caspase activation). On the other hand, meriolins and second generation roscovitine analogs induce a classical apoptosis due to CDK9 inhibition, thus leading to disappearance of the cell survival factor, Mcl-1. These three classes of chemicals display promising anti-proliferative and antitumor properties
Bridoux, Lucie. "Effet de l’inhibiteur tissulaire des métalloprotéinases-1 (TIMP-1) dans les cellules érythroïdes normales et cancéreuses humaines. Caractérisation du récepteur". Reims, 2009. http://theses.univ-reims.fr/exl-doc/GED00001015.pdf.
Texto completoBesides its ability to inhibit MMP activity, TIMP-1 exhibits other biological functions such as mitogenic and anti-apoptotic effects on various cell lines. We showed that TIMP-1 induced UT-7 erythroid cell survival through activation of the JAK2/PI 3-kinase/Akt pathway. Recently, we showed that TIMP-1 specifically bound to pro-MMP-9 localized at the UT-7 plasmic membrane and that pro-MMP-9 membrane expression is crucial for TIMP-1 anti-apoptotic effect. In a first part, we showed that CD44 anchored pro-MMP-9 at the cell surface and that this protein played a crucial role in TIMP-1 anti-apoptotic effect since CD44 silencing abrogated pro-MMP-9 cell surface localisation and enabled TIMP-1-mediated cell survival. In TIMP-1 anti-apoptotic signalling pathway, JAK2 is the first tyrosin kinase phosphorylated following TIMP-1 stimulation. In a second part, we studied the interaction between CD44 and tyrosin kinase JAK2. We showed that CD44 is associated in a constitutive manner to JAK2 via the JAK2 FERM domain. Other kinases could be implicated in TIMP-1 anti-apoptotic pathway, among them the Src kinases. In a third part, we studied the implication of Lyn Src kinase in TIMP-1 effect. We showed that Lyn played a crucial role in TIMP-1 anti-apoptotic effect upstream the PI 3-kinase
Cot, Emilie. "Inhibition chimique des Cdk : mécanisme biochimiques et conséquences cellulaires". Thesis, Montpellier 2, 2010. http://www.theses.fr/2010MON20054.
Texto completoCycline Dependant Kinases (Cdk) control cell cycle progression. The study of their roles is often difficult because of functional redundancy; when a given Cdk is absent, others may compensate. The main role of Cdk2 in the cell cycle is in the initiation of DNA replication, but absence of Cdk2 is compensated for by Cdk1. For example, mice with a genetic knockout of Cdk2 are viable. The chemical inhibition of Cdks may limit compensation by other Cdks. Therefore, to study Cdk2 roles, we have studied chemical inhibition by NU6102, which seems to be selective for Cdk2 in the Xenopus model. To verify the selectivity and study parameters that determine selectivity, we have designed and produced mutants of Cdk2 which are resistant to NU6102, allowing restoration of function in the presence of inhibitor. Moreover, we demonstrate in vitro that NU6102 is selective for Cdk2 compared to other human Cdks, and we describe phenotypes induced by NU6102 in cultured cells, which are interesting in the light of potential applications of NU6102 in cancer chemotherapy. Cdk activity is essential for initiation of DNA replication, but in metazoans no essential substrates are known. To identify potential Cdk substrates during DNA replication, we have performed a proteomics screen of the proteins loaded onto chromatin in the presence or absence of Cdk activity, in the Xenopus model. The results suggest that Cdk activity is not only required for assembling DNA replication complexes onto origins of replication, but may also be implicated in other cellular functions
Fourmentraux, Emmanuelle. "Modulation de l'activité lymphocytaire T CD4⁺ par le récepteur inhibiteur KIR2DL1". Paris 7, 2009. http://www.theses.fr/2009PA077022.
Texto completoThe functional activity of immune cells is controlled by a balance between activators and inhibitors signals. The Inhibitory killer Ig-like receptors (KIR) expressed on NK cells and memory effectors T-cell recognize the CMH-I molecules and inhibit cellular activation by SHP-1 recruitment. To better understand the fonction of KIR receptors on CD4⁺ T-cells, KIR2DL1 transfectants were obtained from human T-cell line and from primary CD4⁺ T-cells. Following TCR stimulation, IL-2 production is increased in CD4+ T cells transfected by KIR2DL1 independently of its engagement. When KIR2DL1 is engaged by its cognate ligand the TCR activation is inhibited. Co-stimulation of the TCR signaling by KIR2DL1 requires intact ITIM and their phosphorylation. It induces a subséquent SHP-2 recruitment and an increased of PKCθ and ERK phosphorylation. Synapses leading to activation are characterized by an increase in the recruitment of p-Tyr, SHP-2, and p-PKCθ. Interaction of KIR2DL1 with its ligand leads to a strong synaptic KIR2DL1 accumulation and SHP-1/SHP-2 recruitment resulting in the inhibition of TCR-induced IL-2 production. These data reveal that KIR2DL1 may induce two opposite signaling outputs in CD4⁺ T cells, depending on whether the KIR receptor is bound to its ligand. The unexpected results observed on the regulation of CD4⁺ T cells by KIR2DL1 receptors, through the functional duality of ITIM, is fundamental to determine the immune System capacity to develop an adapted answer, i. E. To maintain the balance between tolerance and immunity
Tikad, Abdellatif. "Développement de nouvelles pyrido[3,2-d]pyrimidines polyfonctionnalisées : application à la synthèse d’inhibiteurs de CDKs". Orléans, 2008. http://www.theses.fr/2008ORLE2079.
Texto completoPouche, Lucie. "Variabilité d'origine génétique et épigénétique de la pharmacodynamie des inhibiteurs de la calcineurine en transplantation rénale". Thesis, Limoges, 2016. http://www.theses.fr/2016LIMO0017/document.
Texto completoInter-individual genetic variation might account for diverse efficacy and toxicity of calcineurin inhibitors (cyclosporin and tacrolimus). In particular, some variants located within genes coding for proteins of the calcineurin pathway can explain part of this variability. In this manuscript, a panel of candidate genes was selected based on bibliographic review and tested in a pharmacogenetics study encompassing 381 renal transplants followed for one year after surgery. None of these candidates was associated with the acute rejection or serious infection risks. Furthermore, the pharmacodynamic variability of these drugs was also investigated, exploring the use of epigenomics profiling as proximal readout of the calcineurin inhibition treatment. In particular, we investigated the impact of drug exposure on DNA methylation in two experimental models. Methylated DNA immunoprecipitation followed by high-throughput sequencing (MeDIP-seq, Ion Proton technology) was deployed in JURKAT cell line, used as in vitro model, and in CD4 T lymphocytes isolated from mice treated with either cyclosporin or tacrolimus for three months. After sequencing, the differentiated methylated regions caused by drug exposure were analyzed. Bioinformatics analyses were performed using SAMtools (Li et al., 2009), BEDtools (Quinlan and Hall, 2010), MACS2 (Zhang et al., 2008) and Diffbind (Stark and Brown, 2011 - Bioconductor). Overall, the genome-wide analysis revealed only 24 regions with a differentiated enrichment in DNA methylation after three month-tacrolimus treatment, indicating a targeted effect of these treatments on a subset of key genes. Of note, CALM2 promoter, coding for the calmodulin isoform 2 protein, showed significant hypermethylation in tacrolimus-treated mice. These preliminary results corroborate the interest in using DNA methylation as promising approach to identify candidate biomarkers for therapeutic drug monitoring in calcineurin inhibitor treatments